Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

survival of 33 weeks and an interim median overall survival of 41 weeks. Patient enrollment in this trial has surpassed the half-way mark.

More than 70 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with long-term surviving patients from early GBM clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from the time of disease recurrence.

Overall, Cotara has been administered to a total of more than 120 patients with brain, colon, liver or other cancers. Promising data from these studies support Cotara's ability to specifically target solid tumors and its anti-tumor activity, as well as its acceptable safety profile.

About Cotara®

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The new , Healthcare ... , available today on PharmaBoardroom.com for free ... that rocked the Spanish economy in 2009, and the austerity ... has remained pragmatic in times of trouble. "Despite ... fifth biggest European market, and the general conditions to invest ...
(Date:9/18/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... and China Acetic Acid Industry" is a professional ... and Global Acetic Acid Market. The ...
(Date:9/18/2014)... 18, 2014 Texas Governor Rick ... Texas A&M Health Science Center CEO Brett Giroir, ... Health and Human Services (HHS), State of Texas ... pandemic influenza vaccine manufacturing facility in Bryan, Texas, ... for the Texas A&M Biocorridor – a rapidly ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Human Albumin Industry Report 2014" ... Human Albumin Industry Report 2014 is a professional and ... human albumin industry. The report provides a ... and industry chain structure. The human albumin market analysis ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... PRXL ) has appointed Charles A. Stevens as ... Strategic Reimbursement Services, a,unit based in the Washington, ... dedicated to helping PAREXEL,s clients provide solutions to ... they require. His,responsibilities include managing reimbursement service and ...
... WOODLANDS, Texas, Dec. 10 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... management will participate in the RBC Capital Markets,Healthcare Conference ... at The Westin Times Square Hotel in New York, ... Eastern Time., A live audio webcast of the ...
... Nash Corporation,(Nasdaq: KNSY ) is scheduled to participate ... & Tissue" at the 2007 RBC Capital Markets,Healthcare Conference., ... in the panel,discussion on Thursday, December 13th at 8:00 ... in New York. The conference is by invitation only,however ...
Cached Biology Technology:PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 2PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 3PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 4PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 5Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference 2
(Date:9/18/2014)... system that can operate inside the bore of an ... a biomedical research partnership program at Brigham and Women,s ... the robot, in conjunction with real-time MRI images, can ... and less discomforting for the patient. The novel system ... with greater precision. , Developed by a team of ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... (SALT LAKE CITY)Alternating hemiplegia of childhood (AHC) is a ... episodes of paralysis and stiffness, first affecting one side ... and disappear, again and again, and affected children often ... older, children fall progressively behind their peers in both ...
... smog-filled sky or a contaminated river, according to a ... for the prosperous. People living in China,s cities ... more likely to begreen: re-using their plastic grocery bags ... the international journal AMBIO , indicates that the ...
... doesn,t mean making a trip to the local pharmacy for ... the forest to provide a pharmacopeia of medicines to ... But while questions persist about whether such natural remedies are ... examining the phenomenon from a unique perspective, and trying to ...
Cached Biology News:Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 2Gene mutations linked to most cases of rare disorder -- Alternating Hemoplegia of Childhood 3Pollution can make citizens - both rich and poor - go green 2Health care savings, naturally 2Health care savings, naturally 3
Request Info...
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
Biology Products: